Akebia Therapeutics (AKBA) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Reddit leads social media platforms in revenue growth per user
Akebia Therapeutics (AKBA) PT Raised to $7.50 at H.C. Wainwright
August 12, 2024 6:13 AM EDTH.C. Wainwright analyst Ed Arce raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $7.50 (from $6.00) while maintaining a Buy rating.
The analyst comments "Akebia is focused on the long game, with pre-commercial execution preparing for Vafseo as the standard-of-care. As previously announced, Akebia submitted its TDAPA application in June. Akebia expects to have a CPT code assigned in October 2024 and full TDAPA designation by January 1, 2025. In... More
